CreatorsPublishersAdvertisers
View more in
Cancer

Treatment Advances in Relapsed/Refractory DLBCL

onclive.com
 2021-07-13

Cover picture for the articleA historical overview of treatment advances for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and the rationale for treating appropriate patients with an approved antibody-drug conjugate therapy. Tycel Jovelle Phillips, MD: The current landscape for diffuse large B-cell lymphoma [DLBCL] has been evolving. For frontline therapy, the long-standing win has been...

www.onclive.com

Comments / 0

Comments / 0